NasdaqCM - Nasdaq Real Time Price USD
Dianthus Therapeutics, Inc. (DNTH)
19.59
-1.03
(-5.00%)
At close: May 9 at 4:00:00 PM EDT
19.59
0.00
(0.00%)
After hours: May 9 at 4:26:13 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 2 |
| Avg. Estimate | -0.71 | -0.8 | -3.16 | -2.95 |
| Low Estimate | -0.71 | -0.8 | -3.16 | -3.19 |
| High Estimate | -0.71 | -0.8 | -3.16 | -2.72 |
| Year Ago EPS | -- | -- | -2.16 | -3.16 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 10 | 10 |
| Avg. Estimate | 806.9k | 910.7k | 3.52M | 2.85M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 1.5M | 1.96M | 6.55M | 6.87M |
| Year Ago Sales | 874k | 1.86M | 6.24M | 3.52M |
| Sales Growth (year/est) | -7.68% | -51.12% | -43.62% | -18.98% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.55 | -0.6 | -0.76 |
| EPS Actual | -0.54 | -0.51 | -0.74 | -0.7 |
| Difference | -0.1 | 0.04 | -0.14 | 0.06 |
| Surprise % | -23.29% | 6.52% | -23.13% | 7.91% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.71 | -0.8 | -3.16 | -2.95 |
| 7 Days Ago | -0.71 | -0.8 | -3.16 | -2.95 |
| 30 Days Ago | -0.71 | -0.8 | -3.16 | -2.95 |
| 60 Days Ago | -0.83 | -0.86 | -3.29 | -2.79 |
| 90 Days Ago | -0.83 | -0.86 | -3.29 | -2.79 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| DNTH | -- | -- | -46.06% | 6.49% |
| S&P 500 | 13.21% | 3.06% | 8.01% | 13.77% |
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 3/12/2025 |
| Reiterates | Guggenheim: Buy to Buy | 3/12/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/12/2025 |
| Initiated | TD Cowen: Buy | 12/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/11/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 11/11/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
14.10
+9.64%
APGE Apogee Therapeutics, Inc.
37.29
-1.38%
VRDN Viridian Therapeutics, Inc.
12.39
-3.05%
ELVN Enliven Therapeutics, Inc.
18.42
-1.13%
ORKA Oruka Therapeutics, Inc.
9.54
-2.15%
CLYM Climb Bio, Inc.
1.1900
0.00%
ATXS Astria Therapeutics, Inc.
4.2300
-3.86%
IRON Disc Medicine, Inc.
44.24
-0.11%
CGEM Cullinan Therapeutics, Inc.
7.54
-2.96%
OKUR OnKure Therapeutics, Inc.
1.9200
-4.00%